What Other Options Are Available for Patients Resistant to Ibrutinib?

What additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant, in this “Ask the Expert” session.

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo